Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana Biotechnology (SANA), another player in the cell transplant therapeutic space, has announced positive results for its hypoimmune pancreatic islet cell therapy, which represents a positive signal for the space and further validation of the potential for cell transplant therapies like UP421, OpRegen, and OPC1, the analyst tells investors in a research note. The firm adds however that it is reducing its price target to reflect the dilution from the company’s November financing.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
- Lineage Cell Therapeutics price target raised to $9 from $7 at H.C. Wainwright
- Lineage Therap Announces $66 Million Direct Offering
- Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital
- Lineage Cell Therapeutics Reports Q3 2024 Highlights